Endocrine Abstracts

The discovery of coregulators, such as SRC-1, that augment nuclear receptor activity revolutionized our understanding of hormone action, and provided a new avenue of potential therapeutic targets for a variety of human diseases. Numerous coregulators (comprising coactivators and corepressors) have been identified in the past few years. Remarkably, one of these coregulators (SRA, Steroid receptor RNA Activator) functions as an RNA coactivator of classical nuclear receptors (eg....

Peter J Leedman, Laboratory for Cancer Medicine and School of Medicine & Pharmacology, Perth, Australia AbstractPeter Leedman graduated in Medicine at the University of Western Australia (UWA) in 1981, then moved to Melbourne for specialist training in Endocrinology in 1988. He completed PhD studies at the Walter and Eliza Hall Institute of Medical Research (WEHI) with Len Harrison in Melbourne in 1991 and a then p...

The primary treatment for prostate cancer (PCa) involves androgen ablation, halting tumour growth through down-regulation of androgen-regulated proliferative genes1. Frequently PCa progresses to an androgen-independent state and untreatable disease. The Androgen receptor (AR) continues to be expressed in many of these tumours, often associated with androgen-independent activation of the AR signalling pathway. Thus, the aim of the study is to understand regulation of...